CCM
AVDL

Condor Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Condor Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,804
Closed -$176K – 165
2017
Q3 		$176K Hold
16,804
– – 0.04% 171
2017
Q2 		$185K Hold
16,804
– – 0.04% 173
2017
Q1 		$163K Hold
16,804
– – 0.04% 173
2016
Q4 		$175K Hold
16,804
– – 0.04% 177
2016
Q3 		$208K Hold
16,804
– – 0.05% 169
2016
Q2 		$180K Hold
16,804
– – 0.04% 169
2016
Q1 		$186K Hold
16,804
– – 0.05% 170
2015
Q4 		$205K Hold
16,804
– – 0.05% 172
2015
Q3 		$274K Hold
16,804
– – 0.07% 161
2015
Q2 		$356K Hold
16,804
– – 0.09% 157
2015
Q1 		$302K Buy
16,804
+6,183
+58% +$96.8K 0.07% 163
2014
Q4 		$182K Hold
10,621
– – 0.05% 162
2014
Q3 		$152K Sell
10,621
-1,963
-16% -$28.2K 0.04% 162
2014
Q2 		$189K Sell
12,584
-5,689
-31% -$68.6K 0.05% 156
2014
Q1 		$245K Hold
18,273
– – 0.07% 144
2013
Q4 		$147K Sell
18,273
-11,536
-39% -$81.4K 0.05% 152
2013
Q3 		$196K Sell
29,809
-18,377
-38% -$113K 0.07% 154
2013
Q2 		$296K Buy
+48,186
New +$249K 0.11% 138

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Condor Capital Management's AVDL Position: Q4 2017 in Review

Condor Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2017, closing a stake of 16,804 shares — an estimated $176K sold.

Condor Capital Management first reported a position in AVDL in Q2 2013 and held it in 18 quarters. The position peaked at $356K in Q2 2015. 83 funds tracked by Wall St. Rank hold AVDL as of Q4 2017.

  • Condor Capital Management reported no remaining Avadel Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Condor Capital Management sold 16,804 Avadel Pharmaceuticals shares in Q4 2017, an estimated $176K.
  • Condor Capital Management first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Condor Capital Management's Avadel Pharmaceuticals position peaked at $356K in Q2 2015.
  • 83 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2017.

Based on Condor Capital Management's 13F filing for Q4 2017, filed 8 Feb 2018.